JamesHardingMD

Gastrointestinal Cancer

Assistant Attending, Gastrointestinal Oncology Service, Early Drug Development Service, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Harding

Dr. James J. Harding is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College. He specializes in Gastrointestinal Cancer with a clinical and research focus on liver and biliary tract cancers.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(414) 269-3839

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2007 - 2010
Albert Einstein College of MedicineClass of 2007

Certifications & Licensure

NY State Medical License 2008 - 2026
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
Completed
Phase 2
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Start of enrollment: 2014 Mar 07
Completed
Phase 1, Phase 2
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma Start of enrollment: 2014 Nov 01
Terminated
Phase 1, Phase 2
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07
Terminated
Phase 1
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Start of enrollment: 2015 Dec 07
Completed
Phase 3
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients Start of enrollment: 2015 Dec 01
Completed
Phase 1
PF-06671008 Dose Escalation Study in Advanced Solid Tumors Start of enrollment: 2016 Apr 28
Terminated
Phase 1
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors Start of enrollment: 2016 Jun 20
Completed
Phase 1, Phase 2
A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Start of enrollment: 2017 Apr 12
Completed
Phase 1
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer Start of enrollment: 2017 Apr 28
Active, not recruiting
Early Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
Study of GNS561 in Patients With Liver Cancer Start of enrollment: 2018 Apr 04
Terminated
Phase 1, Phase 2
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) Start of enrollment: 2020 Jan 10
Recruiting
Phase 2
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2020 Mar 11
Completed
Phase 1
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Start of enrollment: 2020 Oct 16
Active, not recruiting
Phase 1
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors Start of enrollment: 2017 Jun 01
Terminated
Phase 1, Phase 2
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) Start of enrollment: 2022 Jun 28
Terminated
Phase 1
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer Start of enrollment: 2022 May 05
Recruiting
Phase 1, Phase 2
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations Start of enrollment: 2022 Apr 18
Active, not recruiting
Phase 1
Roles: Contact
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Start of enrollment: 2022 Nov 25
Recruiting
Phase 2
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Start of enrollment: 2023 Nov 09
Recruiting
Phase 1
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Start of enrollment: 2023 Mar 23
Recruiting
Phase 1, Phase 2
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Start of enrollment: 2024 Jun 30
Recruiting
Phase 3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) Start of enrollment: 2023 Dec 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

260 citations
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Bastien Nguyen, Christopher Fong, Anisha Luthra, Shaleigh A Smith, Renzo G DiNatale
Cell. 2022-02-03
66 citations
Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
A. Rose Brannon, Gowtham Jayakumaran, Monica Diosdado, Juber Patel, Anna Razumova
Nature Communications. 2021-06-18
352 citations
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding, Subhiksha Nandakumar, Joshua Armenia, Danny N. Khalil, Melanie Albano
Clinical Cancer Research. 2019-04-01

Lectures

Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepato...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular car...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
ADI-PEG 20 and FOLFOX6: A phase 1 study in pts (pts) with advanced hepatocellular carcinoma (HCC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Treatment Options for Advanced HCC Patients Who Are Not Eligible for IO First LineMarch 14th, 2023
Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of Its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019July 3rd, 2019
Anti–TIM-3 Antibody Well Tolerated as Monotherapy and in Combination with Anti–PD-L1 AntibodyApril 10th, 2019
Join now to see all

Professional Memberships

Alpha Omega Alpha Honor Medical Society - AOA
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member